Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Omni Bio Pharmaceutical, Inc. (OMBP) Reports Favorable Mouse Study Results Of Fc-AAT Molecule 0 comments
    Mar 18, 2013 10:26 AM | about stocks: OMBP

    Omni Bio Pharmaceutical, a biopharmaceutical company focused on the commercialization of novel uses of alpha-1 antitrypsin (NYSE:AAT), today reported study results for the company's recombinant molecule, Fc-AAT, suggesting its potential to treat refractory gout and other inflammatory conditions.

    Leo A. B. Joosten, PhD, of the Radboud University Medical Center, Nijmegen, The Netherlands, detailed the findings of several of his studies in mouse models of gouty arthritis, which showed that Fc-AAT:

    • Suppressed pro-inflammatory responses

    • Exhibited a reduction of 85% in these parameters at a relatively low dose of 50 µg (2 mg/kg per mouse) that was at least as effective as a high dose (10mg/mouse) of the IL1 receptor antagonist anakinra

    • Was at least 40 times more potent than a clinical grade of plasma-derived AAT

    • Exhibited a prolonged duration of action relative to plasma-derived AAT

    Additionally, the study also demonstrated Fc-AAT's unique mechanism of anti-inflammatory action that occurs through modulation of TLR2 and TLR4 expression, suppression of a variety of pro-inflammatory cytokine mediators, inhibition of capsase-1 activation, and induction of IL1 receptor antagonism.

    "These results are very exciting and suggest that Fc-AAT has high potential for use in the treatment of refractory gout and other inflammatory conditions. We are now considering how best to pursue early clinical trials in patients suffering from this condition," Dr. Joosten stated in the press release.

    While current treatments require that AAT-deficient patients travel to a doctor's office or infusion center for weekly intravenous infusions, Omni Bio's treatment option in the future may be available for self-administration.

    "Findings such as these continue to validate the broad potential for the use of AAT in several inflammatory conditions and also highlight the potential for our recombinant Fc fusion molecule to be used in a low-dose, self-administered subcutaneous format," Omni Bio's Chief Scientific Officer Dr. Charles Dinarello stated.

    For more information, visit omnibiopharma.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: OMBP
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.